ArticleRheumatology international2016
Prevalence of antinuclear antibodies in healthy Lebanese subjects, 2008-2015: a cross-sectional study involving 10,814 subjects.
Article in Rheumatology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 19 citations in OpenAlex.
- Prevalence and correlates of antinuclear antibodies in a Japanese community sample: a cross-sectional study.Current therapeutic research, clinical and experimental · 2026Article
- [Humoral Immunity Abnormalities in Advanced Maternal-Age Women With Recurrent Spontaneous Abortion: A Single Center Study].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Article
- Clinical usefulness of anti-nuclear antibody in childhood: real-world experience at a tertiary care center : Usefulness of ANA in pediatric autoimmune diseases.European journal of pediatrics · 2023Article
- The effect of the BNT162b2 vaccine on antinuclear antibody and antiphospholipid antibody levels.Immunologic research · 2022Article
- The influence of demography and referral medical specialty on the detection of autoantibodies to HEP-2 cells in a large sample of patients.Advances in rheumatology (London, England) · 2022Article
- Prevalence of antinuclear antibodies in inflammatory bowel disease and seroconversion after biological therapy.Therapeutic advances in gastroenterology · 2022Article
- Antinuclear Antibody Profiling in Patients of a Tertiary Care Centre in Central India.Indian journal of clinical biochemistry : IJCB · 2021Article
- Antinuclear Autoantibodies in Health: Autoimmunity Is Not a Synonym of Autoimmune Disease.Antibodies (Basel, Switzerland) · 2021Review
- Autoimmune liver disease-associated serologic profiling in Chinese patients with acute hepatitis E virus infection.Immunologic research · 2021Article
- [Clinical and laboratory characteristics of rheumatoid arthritis with positive antinuclear antibody].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2020Article
- Autoimmune hepatitis in human immunodeficiency virus-infected patients: A case series and review of the literature.World journal of gastroenterology · 2019Review
- Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antinuclear antibodies (ANA) are found at varying frequencies in healthy populations, depending on geographical location and ethnic background of participants. The main objective of this study was to determine the prevalence of ANA in healthy Lebanese population in the period 2008-2015. Study subjects comprised 10,851 individuals (3311 males and 7503 females). ANA positivity was determined using immunofluorescence on HEp-2 cells. The prevalence of positive ANA test at a titer of ≥1:100 was 26.4 %, with 696 individuals (6.4 %) having titers exceeding 1:100. Most ANA-positive cases were recorded between 2013 and 2015, which reflected increased assay sensitivity. ANA positivity was associated with increased age and with female gender. Significant increases in ANA positivity were seen with advanced age, with steady increases from the 30- to 40-year age group through the >70-year age group, with significantly higher prevalence noted in female participants. There was a steady and significant reduction in the number of ANA-positive cases with higher ANA titers, which ranged from 20.0 % (1/100) to 3.7 % (1/320), 1.7 % (1/640), and 1.1 % (1/1000). While 45 % of low ANA titer was seen in 31-60-year age category, compared with 19.8 % for 61+ year category, the distribution of high ANA titer was more uniform between 31+ year age categories, which ranged from 11.4 % (31-40 years) to 12.4 % (>70 years). This was consistently and significantly higher in female participants. The prevalence and distribution of ANA among Lebanese individuals were comparable to the rates established for Western countries and confirm the contribution of female gender and advanced age to ANA positivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.